Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients

Daniela Schiesser1, Isabelle Binet2, Dimitrios Tsinalis2, Michael Dickenmann3, Gérald Keusch4, Markus Schmidli5, Patrice M. Ambühl6, Liudmila Lüthi6 and Rudolf P. Wüthrich6

Cantonal Hospitals of 1Walenstadt, 2St Gallen and 5Herisau, 4Waid City Hospital, University Hospitals 3Basel and 6Zürich, Switzerland

Abstract

Background. Haemodialysis patients need sustained treatment with intravenous iron because iron deficiency limits the efficacy of recombinant human epoetin therapy in these patients. However, the optimal intravenous iron maintenance dose has not been established yet.

Methods. We performed a prospective multicentre clinical trial in iron-replete haemodialysis patients to evaluate the efficacy of weekly low-dose (50 mg) intravenous iron sucrose administration for 6 months to maintain the iron status, and to examine the effect on epoetin dosage needed to maintain stable haemoglobin values in these patients. Fifty patients were enrolled in this prospective, open-label, single arm, phase IV study.

Results. Forty-two patients (84%) completed the study. After 6 months of intravenous iron sucrose treatment, the mean ferritin value showed a tendency to increase slightly from 405 ± 215 mg/l at baseline to 490 ± 275 mg/l at the end of the study, but iron, transferrin levels and transferrin saturation did not change. The haemoglobin level remained stable (12 ± 1.1 at baseline and 12.1 ± 1.5 g/dl at the end of the study). The mean dose of darbepoetin alfa could be reduced from 0.75 to 0.46 mg/kg/week; epoetin alfa was decreased from 101 to 74 IU/kg/week; and the mean dose of epoetin beta could be reduced from 148 to 131 IU/kg/week at the end of treatment.

Conclusions. A regular 50 mg weekly dosing schedule of iron sucrose maintains stable iron stores and haemoglobin levels in haemodialysed patients and allows considerable dose reductions for epoetins. Low-dose intravenous iron therapy may represent an optimal approach to treat the continuous loss of iron in dialysis patients.

Keywords: anaemia; epoetins; haemodialysis; iron sucrose; outcome

Introduction

Iron deficiency is common in haemodialysis patients and limits the efficacy of treatment with epoetin [1]. Intravenous iron therapy is, therefore, required by almost all haemodialysis patients receiving epoetin to achieve the target haemoglobin in the most efficient way [2,3]. The National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI) guidelines and the European Best Practice Guidelines (EBPG) advocate consistent detection and management of iron deficiency [4–7]. According to the revised EBPG for the management of anaemia in patients with chronic renal failure (2004), the serum ferritin target levels should be > 100 μg/l in all patients, but in practice, it is necessary to aim for a ferritin target of 200–500 μg/l to achieve this minimum level of 100 μg/l [7]. The new NKF-DOQI guidelines recommend an even higher minimum ferritin level of > 200 μg/l in haemodialysis patients [5].

The EBPG and the NKF-DOQI guidelines do not give firm recommendations regarding the optimal dose and frequency of intravenous iron administration. Whereas it seems clear that iron-deficient haemodialysis patients need initial iron loading, the maintenance dosing schedule for iron-replete patients still needs to be defined [8]. Based on the results from several studies, a relatively broad dosing range from 25 to 150 mg/week has been recommended [8–12]. With such a broad dosing range there is on the one side a risk of underdosing and also a risk of iron overload on the other [13].

The purpose of the present study was to examine whether a majority of iron-replete haemodialysis patients (ferritin in the range of 200–500 μg/l and transferrin saturation >20%) could maintain their iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
status with a regularly applied low dose of intravenous iron sucrose (50 mg weekly). A secondary goal was to examine whether this iron treatment schedule could reduce the epoetin requirements.

Methods

Study design

The study was designed as a prospective, open-label, single arm, multicentre phase IV study and was performed in accordance with the International Conference of Harmonisation E3 Good Clinical Practice Guidelines and in compliance with the Helsinki declaration. Six hospital dialysis centres participated in the study, and all the local ethics committees approved the study. Written informed consent was obtained from all the patients.

The study population consisted of 50 stable maintenance haemodialysis patients. Male and female patients undergoing maintenance haemodialysis (2–3 sessions per week), 18–75 years of age, were included. All patients had to be iron-replete (serum ferritin 200–800 μg/l; transferrin saturation 20–50%) and were required to display haemoglobin concentrations between 9.0 and 13.5 g/dl on three successive occasions in the past 2 months before the study. All study patients received intravenous iron sucrose, in non-systematic fashion prior to the study inclusion. All study patients were also on epoetin therapy. Furthermore, hypertension was controlled with various blood pressure medications, and secondary hyperparathyroidism was controlled with phosphate binders and vitamin D preparations in all study subjects. The following criteria excluded the patients from the study: suspicion of iron overload (ferritin >800 μg/l; transferrin saturation >50%), active inflammation or infection, malignancy, blood transfusions 3 months prior to and during the study.

Study drug administration

Patients received weekly doses of 50 mg of iron sucrose (Venofer®) for a total of 24 doses. Iron sucrose was injected into the venous limb of the haemodialysis tubing system (slow intravenous push at a rate of 10 mg/min). Iron therapy was stopped if the serum ferritin level exceeded 800 μg/l, but was resumed when the serum ferritin had decreased below 600 μg/l. Treatment failure was defined as a serum ferritin level which dropped below 100 μg/l despite continuous iron sucrose treatment.

Study parameters

Demographic baseline data (age, sex, ethnicity, height, weight and body mass index) were collected at the screening visit. Concomitant medications were also assessed. The epoetin dosage was not subjected to a defined treatment algorithm, but was adjusted in order to maintain the haemoglobin value that was recorded at inclusion. The epoetin dosage and application schedule was recorded throughout the study, and was averaged per month. Mean monthly baseline epoetin doses were calculated as the mean value of weeks −12 to −9, weeks −8 to −5 and weeks −4 to −1.

Iron parameters (serum ferritin, serum iron, transferrin and transferrin saturation), C-reactive protein (CRP) levels and haematological parameters (haemoglobin, haematocrit, red blood cell number and red cell indices (mean cellular volume, MCV; mean cellular haemoglobin, MCH and mean cellular haemoglobin concentration, MCHC) were measured at the screening visit and then monthly, using standard laboratory procedures.

Statistical analyses

All efficacy parameters were analysed using descriptive statistics. Data are reported as mean±SD. SAS® Version 8.02 was the statistical software package used for all data analyses.

Safety measurements

The safety population included all patients who had received at least one dose of the study medication. Recurrent events occurring during haemodialysis (pruritus, leg pain) prior to study entry were recorded. When these events occurred with the same intensity during the study, they were not reported as adverse events. Blood pressure was measured 15 min before and 15 min after each iron sucrose injection as a measure of safety.

Results

The trial population consisted of 28 male and 22 female haemodialysis patients. The mean age was 58.2±12.8 years, the mean weight 72.5±15.4 kg and the mean body mass index 25.8±4.6 kg/m². The study was completed by 42 of the 50 patients (84%). Three patients (6%) terminated the study earlier because of renal transplantation; three patients (6%) had to be withdrawn from the study due to an adverse event which was not related to the study drug application (shunt malfunction; gastrointestinal bleeding; haemothorax); one patient (2%) had to be excluded due to persistently high ferritin values; in one case (2%), serum ferritin levels dropped below 100 μg/ml despite treatment with iron sucrose (treatment failure).

Iron parameters

All the patients were iron-replete at the start of the study. The mean ferritin values were in the optimal target range of 200–500 μg/l as defined by the EBPG. Mean ferritin values showed a non-significant trend to increase (+17.3%) from 405±159 μg/l at baseline to 490±275 μg/l at the end of study (Table 1).

The iron and transferrin mean values did not change significantly, and mean transferrin saturation also did not change during the whole study period (Table 1). Together, these data show that iron stores increased slightly, but there was no sign of iron overload during the 6-month treatment phase.

CRP mean values were 6.8 mg/l at week 0, 7.9 mg/l at week 9, 8.4 mg/l at week 17 and 6.4 mg/l at week 25.
Low-dose intravenous iron sucrose in haemodialysis patients

Table 1. Iron parameters of study population at baseline and during the 26-week study period

<table>
<thead>
<tr>
<th>Week</th>
<th>Ferritin (µg/l)</th>
<th>Iron (µmol/l)</th>
<th>Transferrin (g/l)</th>
<th>TSAT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening</td>
<td>405 ± 159</td>
<td>12.7 ± 3.4</td>
<td>1.7 ± 0.3</td>
<td>29.9 ± 8.1</td>
</tr>
<tr>
<td>Week 1</td>
<td>379 ± 178</td>
<td>13.3 ± 4.1</td>
<td>1.7 ± 0.3</td>
<td>31.3 ± 11.8</td>
</tr>
<tr>
<td>Week 5</td>
<td>430 ± 194</td>
<td>12.7 ± 4.6</td>
<td>1.7 ± 0.3</td>
<td>30.4 ± 13.1</td>
</tr>
<tr>
<td>Week 9</td>
<td>415 ± 157</td>
<td>12.9 ± 4.5</td>
<td>1.7 ± 0.3</td>
<td>31.0 ± 10.9</td>
</tr>
<tr>
<td>Week 13</td>
<td>420 ± 170</td>
<td>13.5 ± 5.1</td>
<td>1.7 ± 0.3</td>
<td>31.8 ± 13.5</td>
</tr>
<tr>
<td>Week 17</td>
<td>426 ± 185</td>
<td>12.7 ± 3.9</td>
<td>1.7 ± 0.3</td>
<td>30.1 ± 9.7</td>
</tr>
<tr>
<td>Week 21</td>
<td>472 ± 173</td>
<td>13.0 ± 4.6</td>
<td>1.7 ± 0.2</td>
<td>31.7 ± 11.8</td>
</tr>
<tr>
<td>End of study</td>
<td>490 ± 275</td>
<td>13.3 ± 4.0</td>
<td>1.7 ± 0.2</td>
<td>31.2 ± 10.5</td>
</tr>
</tbody>
</table>

Data are mean ± SD. Mean ferritin levels increased by 17.3%.

Table 2. Haematological parameters (haemoglobin and red cell indices [MCV, MCH, MCHC])

<table>
<thead>
<tr>
<th>Week</th>
<th>Hb (g/dl)</th>
<th>MCV (fl)</th>
<th>MCH (pg)</th>
<th>MCHC (g/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening</td>
<td>12.1 ± 1.1</td>
<td>95.0 ± 6.8</td>
<td>31.3 ± 2.6</td>
<td>33.0 ± 1.2</td>
</tr>
<tr>
<td>Week 1</td>
<td>12.2 ± 1.1</td>
<td>95.5 ± 6.7</td>
<td>31.4 ± 2.5</td>
<td>32.8 ± 1.0</td>
</tr>
<tr>
<td>Week 5</td>
<td>12.2 ± 1.0</td>
<td>95.4 ± 6.1</td>
<td>31.5 ± 2.4</td>
<td>32.9 ± 1.2</td>
</tr>
<tr>
<td>Week 9</td>
<td>12.4 ± 1.1</td>
<td>95.6 ± 6.1</td>
<td>31.6 ± 2.4</td>
<td>33.1 ± 1.0</td>
</tr>
<tr>
<td>Week 13</td>
<td>12.3 ± 0.9</td>
<td>96.5 ± 6.6</td>
<td>31.8 ± 2.5</td>
<td>32.9 ± 1.2</td>
</tr>
<tr>
<td>Week 17</td>
<td>12.4 ± 1.0</td>
<td>96.2 ± 6.0</td>
<td>31.8 ± 2.5</td>
<td>33.1 ± 1.1</td>
</tr>
<tr>
<td>Week 21</td>
<td>12.4 ± 0.9</td>
<td>95.9 ± 6.2</td>
<td>31.9 ± 2.5</td>
<td>33.2 ± 1.1</td>
</tr>
<tr>
<td>End of study</td>
<td>12.1 ± 1.5</td>
<td>95.9 ± 6.4</td>
<td>31.7 ± 2.4</td>
<td>33.1 ± 1.1</td>
</tr>
</tbody>
</table>

Data are mean ± SD. Haemoglobin values remained stable and the red cell indices did not change.

Table 3. Monthly dosage of epoetins (standardized values)

<table>
<thead>
<tr>
<th>Period</th>
<th>Darbepoetin alfa (µg)</th>
<th>Epoetin alfa (IU)</th>
<th>Epoetin beta (IU)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>n = 14</td>
<td>n = 13</td>
<td>n = 19</td>
</tr>
<tr>
<td>Mean baseline (weeks -12 to -1)</td>
<td>221 ± 159</td>
<td>28 578 ± 13 411</td>
<td>36 894 ± 20 404</td>
</tr>
<tr>
<td>Weeks 1–4</td>
<td>237 ± 159</td>
<td>24 533 ± 13 405</td>
<td>32 310 ± 20 697</td>
</tr>
<tr>
<td>Weeks 5–8</td>
<td>195 ± 122</td>
<td>21 867 ± 14 745</td>
<td>32 619 ± 17 912</td>
</tr>
<tr>
<td>Weeks 9–12</td>
<td>179 ± 112</td>
<td>24 533 ± 13 384</td>
<td>32 190 ± 15 069</td>
</tr>
<tr>
<td>Weeks 13–16</td>
<td>172 ± 112</td>
<td>26 133 ± 15 829</td>
<td>32 095 ± 15 437</td>
</tr>
<tr>
<td>Weeks 17–20</td>
<td>142 ± 89</td>
<td>28 714 ± 17 144</td>
<td>33 368 ± 14 758</td>
</tr>
<tr>
<td>Weeks 21–24</td>
<td>136 ± 90</td>
<td>26 769 ± 18 376</td>
<td>33 842 ± 15 643</td>
</tr>
</tbody>
</table>

Data are mean ± SD. The dosage for the three epoetins decreased by 38.5% [darbepoetin alfa (Aranesp®)], 6.3% [epoetin alfa (Eprex®)] and 8.3% [epoetin beta (Recormon®)].

These CRP values were in the normal range, indicating the absence of systemic inflammation and infection during the study.

**Haematological parameters**

The mean haemoglobin values did not change from the baseline screening period to the end of the study (Table 2). The mean haemoglobin of 12.1 g/dl demonstrates that the patients were in the target range, as defined by the EBPG and K/DOQI guidelines. Table 2 also shows the red cell indices. MCV, MCH and MCHC were in the normal range during the entire study and did not change significantly.

**Epoetin requirement**

The changes in epoetin dosage are shown in Table 3. The monthly doses of the epoetins decreased markedly from the mean monthly values of weeks −12 to −1 (baseline phase) prior to the study to weeks 21 to 24 (assessment phase). The dosage for the three different epoetins decreased by 38.5% [darbepoetin alfa (Aranesp®)], 6.3% [epoetin alfa (Eprex®)] and 8.3% [epoetin beta (Recormon®)]. To confirm these data, we calculated the epoetin requirements in relation to the body weight. The mean dose of darbepoetin alfa was reduced with the iron treatment from 0.75 to 0.46 µg/kg/week (−38.7%). The mean dose of epoetin alfa was decreased from 101 to 74 IU/kg/week (−26.7%). For epoetin beta, the mean dose could be reduced from 148 to 131 IU/kg/week (−11.5%) at the end of treatment.

**Safety evaluation**

Another objective of this study was the evaluation of the safety of iron sucrose (Venofer®) given at a dosage...
of 50 mg weekly. This reduced dosing regimen of iron sucrose was well tolerated by the patients. The intention to treat (ITT) population received 1062 iron sucrose doses, corresponding to a total amount of 53 100 mg. Only one adverse event was classified as possibly related to Venofer® by the investigators (swelling of soft tissue of unclear reason in different locations). None of the patients died. Hypotensive episodes were not reported. The mean systolic and diastolic blood pressures were unchanged prior to and after the iron sucrose administration throughout the study (Figure 1).

Discussion

The optimal intravenous iron dose required to maintain an iron-replete state in maintenance haemodialysis patients has not been defined yet. Therefore, a standardized approach to apply intravenous iron in iron-replete patients is lacking, and many dialysis centres have only insufficient treatment concepts [13,14]. Commonly, iron is applied only when iron deficiency is overt. Iron is then administered in relatively large doses, for weeks to months, and treatment is interrupted until ferritin levels drop below 100 μg/l. This erratic treatment regime induces marked fluctuations of haemoglobin levels, and the subsequent epoetin dosages also need to be adapted frequently. Since there is a slight and continuous loss of blood and iron in haemodialysis patients, a better concept would be to apply intravenous iron as regularly as possible but in low dosage [9,10].

Our study demonstrates that the regular application of 50 mg of intravenous iron sucrose (Venofer®) is able to maintain and even to improve iron parameters in iron-replete haemodialysis patients. Additionally, this regimen allowed to markedly reduce the dosages of epoetin during the treatment. Therefore, iron sucrose can safely and conveniently be applied on a weekly basis. Together with a weekly application of epoetin, this improves anaemia management considerably by decreasing epoetin requirement, increasing adherence by patients and simplifying the application by the nursing staff.

Other investigators have tested various parenteral maintenance iron regimes [8–12,15–20]. However, most studies have been performed in iron-deficient patients or in patients with functional iron deficiency. Based on some of these studies, a recommendation of 2–3 g iron per year was calculated for haemodialysis patients. Therefore, a weekly 50 mg dosing schedule (approximately 2.5 g per year) would seem to be appropriate for the majority of haemodialysis patients. Of course, this treatment scheme has limitations, and it may not be suitable for patients with bleeding, patients with inflammation and malnutrition and for patients with obvious iron deficiency. We speculate, however, that the regular 50 mg weekly dose could be applied to >80% of the stable haemodialysis patients.

Treatment beyond 6 months, however, would need monitoring to exclude long-term iron overload. This risk seems minor though, as many dialysis patients will eventually need some type of access procedure (percutaneous transluminal angioplasty or surgery) with subsequent blood loss, or may have some other form of bleeding (clotting of dialyser, gastro-intestinal bleeding). Thus, there will be increased blood loss, which will again require larger amounts of iron or even transfusions.

In summary, a weekly 50 mg iron sucrose intravenous dosing scheme maintains stable iron parameters and haemoglobin values in iron-replete haemodialysis patients. The regular application of 50 mg iron sucrose allows considerable epoetin dose reductions. Low-dose iron sucrose dosing may represent an optimal approach in treating the continuous loss of iron in haemodialysis patients.

Acknowledgements. The authors thank Vifor International AG (St Gallen, Switzerland) for the investigational drug and for financial support to perform this study.

Conflict of interest statement. R.P.W. is serving as a scientific consultant for Vifor International AG (St Gallen, Switzerland).

References


Received for publication: 10.3.06
Accepted in revised form: 19.6.06